Display options
Cite
Vasques-Monteiro IML, Souza-Mello V. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight. World J Gastroenterol. 2021;27(16):1738-1750doi: 10.3748/wjg.v27.i16.1738.
Vasques-Monteiro, I. M. L., & Souza-Mello, V. (2021). Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight. World journal of gastroenterology, 27(16), 1738-1750. https://doi.org/10.3748/wjg.v27.i16.1738
Vasques-Monteiro, Isabela Macedo Lopes, and Souza-Mello, Vanessa. "Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight." World journal of gastroenterology vol. 27,16 (2021): 1738-1750. doi: https://doi.org/10.3748/wjg.v27.i16.1738
Vasques-Monteiro IML, Souza-Mello V. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight. World J Gastroenterol. 2021 Apr 28;27(16):1738-1750. doi: 10.3748/wjg.v27.i16.1738. PMID: 33967554; PMCID: PMC8072197.
Copy Download .nbib Format: NLM
Share it on

World J Gastroenterol. 2021 Apr 28;27(16):1738-1750. doi: 10.3748/wjg.v27.i16.1738.

Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight.

World journal of gastroenterology

Isabela Macedo Lopes Vasques-Monteiro, Vanessa Souza-Mello

Affiliations

  1. Anatomy, Rio de Janeiro State University, Rio de Janeiro 20551030, Brazil.

PMID: 33967554 PMCID: PMC8072197 DOI: 10.3748/wjg.v27.i16.1738

Abstract

The coronavirus disease 2019 (COVID-19) outbreak has drawn the scientific community's attention to pre-existing metabolic conditions that could aggravate the infection, causing extended viral shedding, prolonged hospitalization, and high death rates. Metabolic dysfunction-associated fatty liver disease (MAFLD) emerges as a surrogate for COVID-19 severity due to the constellation of metabolic alterations it entails. This review outlines the impact MAFLD exerts on COVID-19 severity in obese subjects, besides the possible mechanistic links to the poor outcomes. The data collected showed that MAFLD patients had poorer COVID-19 outcomes than non-MAFLD obese subjects. MAFLD is generally accompanied by impaired glycemic control and systemic arterial hypertension, both of which can decompensate during the COVID-19 clinical course. Also, MAFLD subjects had higher plasma inflammatory marker concentrations than non-MAFLD subjects, which might be related to an intensified cytokine storm syndrome frequently associated with the need for mechanical ventilation and death. In conclusion, MAFLD represents a higher risk than obesity for COVID-19 severity, resulting in poor outcomes and even progression to non-alcoholic steatohepatitis. Hepatologists should include MAFLD subjects in the high-risk group, intensify preventive measurements, and prioritize their vaccination.

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Keywords: COVID-19; Cytokine storm syndrome; Metabolic dysfunction-associated fatty liver disease; Obesity; Severity

Conflict of interest statement

Conflict-of-interest statement: The authors have nothing to disclose.

References

  1. Front Physiol. 2018 Dec 18;9:1813 - PubMed
  2. N Engl J Med. 2020 Jun 11;382(24):2372-2374 - PubMed
  3. Nat Rev Immunol. 2019 Aug;19(8):477-489 - PubMed
  4. Lancet Neurol. 2020 Sep;19(9):767-783 - PubMed
  5. Circ Res. 2020 Jun 5;126(12):1671-1681 - PubMed
  6. Metabolism. 2019 Mar;92:82-97 - PubMed
  7. Metabolism. 2017 Sep;74:1-9 - PubMed
  8. J Nucl Med. 2020 May;61(5):632-636 - PubMed
  9. Metabolism. 2015 Jan;64(1):60-78 - PubMed
  10. JGH Open. 2020 Aug 04;: - PubMed
  11. Diabetes Care. 2020 Jul;43(7):e72-e74 - PubMed
  12. J Hepatol. 2020 Aug;73(2):451-453 - PubMed
  13. Lancet Respir Med. 2020 Apr;8(4):420-422 - PubMed
  14. Obesity (Silver Spring). 2020 Jul;28(7):1191-1194 - PubMed
  15. Nature. 2006 Dec 21;444(7122):1027-31 - PubMed
  16. Mod Pathol. 2020 Nov;33(11):2147-2155 - PubMed
  17. Heart Rhythm. 2020 Nov;17(11):1984-1990 - PubMed
  18. Dig Dis Sci. 2020 Sep 27;: - PubMed
  19. J Hepatol. 2016 Jun;64(6):1403-15 - PubMed
  20. Front Immunol. 2020 Oct 30;11:570251 - PubMed
  21. Hepatology. 2016 Jul;64(1):73-84 - PubMed
  22. Metabolism. 2020 Jun;107:154216 - PubMed
  23. JHEP Rep. 2019 Feb 23;1(1):30-43 - PubMed
  24. Diabetes Obes Metab. 2010 May;12(5):365-83 - PubMed
  25. Front Microbiol. 2019 Jan 29;10:50 - PubMed
  26. Gastroenterology. 2020 May;158(7):1999-2014.e1 - PubMed
  27. Metabolism. 2020 Jul;108:154244 - PubMed
  28. Diabetes Metab Syndr. 2020 Sep - Oct;14(5):825-827 - PubMed
  29. SN Compr Clin Med. 2020 Nov 6;:1-4 - PubMed
  30. J Hepatol. 2020 Sep;73(3):719-721 - PubMed
  31. Metabol Open. 2020 Dec;8:100057 - PubMed
  32. Atherosclerosis. 2015 Jul;241(1):27-35 - PubMed
  33. Dig Liver Dis. 2021 Feb;53(2):153-157 - PubMed
  34. Pathobiology. 2021;88(1):88-94 - PubMed
  35. Ann Hepatol. 2021 Jan-Feb;20:100271 - PubMed
  36. Liver Int. 2020 Oct;40(10):2515-2521 - PubMed
  37. J Clin Lab Anal. 2020 Jul;34(7):e23391 - PubMed
  38. Ann Hepatol. 2020 Jul - Aug;19(4):359-366 - PubMed
  39. Nutrients. 2015 Nov 13;7(11):9453-74 - PubMed
  40. Clin Liver Dis. 2009 Nov;13(4):545-63 - PubMed
  41. Metabolism. 2011 Jun;60(6):749-53 - PubMed
  42. Metabolism. 2016 Aug;65(8):1062-79 - PubMed
  43. Minerva Endocrinol. 2017 Jun;42(2):92-108 - PubMed
  44. Int J Infect Dis. 2020 May;94:44-48 - PubMed
  45. J Pathol. 2004 Jun;203(2):631-7 - PubMed
  46. J Endocrinol. 2020 Oct;247(1):11-24 - PubMed
  47. Chest. 2018 Mar;153(3):702-709 - PubMed
  48. Cell Metab. 2012 Jul 3;16(1):44-54 - PubMed
  49. Nat Med. 2011 Feb;17(2):179-88 - PubMed
  50. Biochimie. 2020 Dec;179:257-265 - PubMed
  51. J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331 - PubMed
  52. Sci Rep. 2017 Mar 16;7:44612 - PubMed
  53. Biochem Biophys Res Commun. 2020 May 21;526(1):135-140 - PubMed
  54. BMJ. 2020 May 22;369:m1966 - PubMed
  55. Chin Med J (Engl). 2020 Dec 14;134(1):8-19 - PubMed
  56. ACS Chem Neurosci. 2020 Jun 3;11(11):1520-1522 - PubMed
  57. Adv Exp Med Biol. 2018;1061:111-125 - PubMed
  58. Am J Physiol Endocrinol Metab. 2019 Oct 1;317(4):E710-E722 - PubMed
  59. Liver Int. 2020 Jun;40(6):1278-1281 - PubMed
  60. Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165857 - PubMed
  61. J Clin Transl Hepatol. 2020 Mar 28;8(1):13-17 - PubMed
  62. Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32 - PubMed
  63. Nat Genet. 2008 Dec;40(12):1461-5 - PubMed
  64. Diabetes. 2013 Sep;62(9):2997-3004 - PubMed
  65. Hepatol Int. 2020 Sep;14(5):690-700 - PubMed
  66. Gut. 2005 Dec;54(12):1790-6 - PubMed
  67. Indian J Gastroenterol. 2020 Jun;39(3):285-291 - PubMed
  68. Eur J Clin Invest. 2020 Oct;50(10):e13338 - PubMed
  69. Gastroenterology. 2015 Sep;149(3):635-48.e14 - PubMed
  70. JAMA Neurol. 2020 Aug 1;77(8):1018-1027 - PubMed
  71. Trends Mol Med. 2013 Aug;19(8):487-500 - PubMed
  72. J Clin Transl Hepatol. 2020 Mar 28;8(1):18-24 - PubMed
  73. Cell Death Discov. 2019 Jun 5;5:101 - PubMed
  74. Lancet Gastroenterol Hepatol. 2020 Aug;5(8):776-787 - PubMed
  75. Eur J Intern Med. 2020 Jul;77:18-24 - PubMed
  76. Hepatol Int. 2020 Sep;14(5):701-710 - PubMed
  77. Int J Cardiol. 2018 May 15;259:198-204 - PubMed
  78. PLoS One. 2020 Oct 8;15(10):e0240400 - PubMed
  79. J Clin Invest. 2005 May;115(5):1343-51 - PubMed
  80. Abdom Radiol (NY). 2020 Sep;45(9):2748-2754 - PubMed
  81. Hepatol Commun. 2020 Aug 06;: - PubMed

MeSH terms

Publication Types